Cullinan Therapeutics
David Meek possesses extensive experience in the pharmaceutical and biopharmaceutical industries, currently serving as a Member of the Board of Directors for Cullinan Therapeutics and uniQure, and as a member of the Board of Councilors for the USC Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences. Previous roles include Chief Executive Officer for Mirati Therapeutics and FerGene, as well as Chief Executive Officer at Ipsen. David held significant positions such as Executive Vice President & President of Oncology at Baxalta and Chief Commercial Officer at Endocyte. David's educational background includes a Bachelor of Arts in Business Administration and Management from the University of Cincinnati.
This person is not in the org chart
This person is not in any teams
Cullinan Therapeutics
1 followers
Cullinan Therapeutics is dedicated to creating new standards of care for patients. We have strategically built a diversified portfolio of clinical-stage assets that inhibit key drivers of disease or harness the immune system to eliminate diseased cells in both oncology and autoimmune diseases. Our portfolio encompasses a wide range of modalities, each with the potential to be best and/or first in class. Anchored in a deep understanding of oncology, immunology, and translational medicine, we create differentiated ideas, identify the most appropriate targets, and select the optimal modality to develop transformative therapeutics across a wide variety of cancer and autoimmune indications.